Evidence map›Paper›PMID 37667362›Full record

Trial reportTrials2023

The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery-a prospective, randomized, controlled, and triple-blinded trial.

Elisabeth Hoerner, Ottokar Stundner, Felix Naegele, Anna Fiala, Nikolaos Bonaros, Peter Mair, Johannes Holfeld, Lukas Gasteiger

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Pectoral Nerve Block II for Cardiac Implantable Electronic Devices.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elisabeth HoernerDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Ottokar StundnerDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Felix NaegeleDepartment of Cardiac Surgery, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria. felix.naegele@i-med.ac.at.ORCID http://orcid.org/0000-0002-9666-341X
Anna FialaDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Nikolaos BonarosDepartment of Cardiac Surgery, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Peter MairDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Johannes HolfeldDepartment of Cardiac Surgery, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Lukas GasteigerDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClassic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultrasound techniques gained popularity and are of growing interest. The pectoralis nerve block II (PECS II) has been shown to provide good postoperative analgesia in modified radical mastectomy and might also be suitable for minimally invasive cardiac surgery.

methodsIn a single center, prospective, triple-blinded, two-group randomized trial, 60 patients undergoing elective, unilateral minimal invasive cardiac surgery will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5% (intervention group) or sodium chloride 0.9% (placebo group). The primary outcome parameter is the overall opioid demand given as intravenous morphine milligram equivalents (MME) during the first 24 h after extubation. Secondary endpoints are the visual analog scale (VAS) 2, 4, 6, 8, 12, and 24 h after extubation, the Overall Benefit of Analgesia Score (OBAS) after 24 h, the interval until extubation, and intensive care unit (ICU) discharge within 24 h, as well as the length of hospital stay (LOS). DISCUSSION: This prospective randomized, controlled, and triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5% helps to decrease the opioid demand in the first 24 h and increases postoperative pain control after minimally invasive cardiac surgery.

trial registrationwww.clinicaltrialsregister.eu ; EudraCT Nr: 2021-005452-11; Lukas Gasteiger MD, November 18, 2021.

Indexed as

Analgesics, OpioidBreast NeoplasmsFemaleHumansMastectomyProspective StudiesRopivacaineAnalgesics, OpioidRopivacaineClinical trialFascial plane blockMinimal invasive cardiac surgeryPECS II block

Identifiers

PMID37667362
PMCPMC10476350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.